Be Bio: bringing the B to cell therapy 

Be Biopharma launched Thursday with a $52 million series A round led by Atlas Venture and RA Capital and a platform to engineer B cells that could overcome the durability, safety and re-dosing challenges of existing cell and gene therapies. 

“The workhorses in the cell and gene therapy world are T cells, hematopoietic stem cells and viral vectors, and all of them have substantial limitations,” co-founder and President Aleks Radovic-Moreno told BioCentury. ...